fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Listed in the December 27, 2023 extract; not in the current extract (September 22, 2026): Gravol Filmkote (00013803), Teva-Dimenate (00021423), Apo-Dimenhydrinate (00363766), PMS-Dimenhydrinate (00586331). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-09-22.xml.

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Dimenhydrinate

All strengths: Limited Use, Reason for Use code 481 required; same patient cost rules

Shared coverage and patient cost rules
StatusLimited Use, Reason for Use code 481 required
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.

Dimenhydrinate Inj 50mg USP · DIN 00392537 · 50 mg/mL · injection solution (with Preservative)

Limited Use, Reason for Use code 481 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 481 (criteria below)
Ontario Limited Use criteria, code 481
Reason for Use code 481 For the management of patients receiving palliative care*. Coverage limit: LU Authorization Period: 1 year Coverage limit: *The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
No interchangeable product listed in the Ontario extract
Dimenhydrinate Inj 50mg USP · DIN 00392537 Manufacturer: Sandoz Canada Inc.; listing date 2017-02-28 Health Canada: Marketed since 2023-03-22 · brand DIMENHYDRINATE INJECTION USP · ATC R06AA11 DIMENHYDRINATE · form Solution · route Intravenous, Intramuscular · ingredients DIMENHYDRINATE 50 MG/ML · company Sandoz canada incorporated · schedule Ethical
Re-check Health Canada status and shortages (live) · Health Canada product record

Dimenhydrinate Inj 50mg USP: Formulary list price $1.38 per unit (the source does not state the unit; exact figure $1.3800). What the ministry pays, not the patient.

Ministry pays: $1.3800 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00392537)

Source record
DIN 00392537: Dimenhydrinate Inj 50mg USP Raw flags: sec12=Y, sec3=Y Item: 562200036; group id 663; item number 1651; lccId 00273; manufacturer id SDZ Source form: Inj Sol (with Preservative); strength: 50mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.3800; ministry $1.3800 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00392537 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3397
Shortage status: resolved shortage (ended May 15, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00392537
Shortage record checked October 6, 2026

Dimenhydrinate Injection USP · DIN 02536536 · 50 mg/mL · injection solution (with Preservative)

Limited Use, Reason for Use code 481 requiredMarketed · checked October 5, 2026
Write on scriptReason for Use code 481 (criteria below)
Ontario Limited Use criteria, code 481
Reason for Use code 481 For the management of patients receiving palliative care*. Coverage limit: LU Authorization Period: 1 year Coverage limit: *The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
No interchangeable product listed in the Ontario extract
Dimenhydrinate Injection USP · DIN 02536536 Manufacturer: Sandoz Canada Inc.; listing date 2026-01-30 Health Canada: Marketed since 2024-08-27 · brand DIMENHYDRINATE INJECTION USP · ATC R06AA11 DIMENHYDRINATE · form Solution · route Intravenous, Intramuscular · ingredients DIMENHYDRINATE 50 MG/ML · company Sandoz canada incorporated · schedule Ethical
Re-check Health Canada status and shortages (live) · Health Canada product record

Dimenhydrinate Injection USP: Formulary list price $1.38 per unit (the source does not state the unit; exact figure $1.3800). What the ministry pays, not the patient.

Ministry pays: $1.3800 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02536536)

Source record
DIN 02536536: Dimenhydrinate Injection USP Raw flags: sec12=Y, sec3=Y Item: 562200053; group id 664; item number 1652; lccId 00426; manufacturer id SDZ Source form: Inj Sol (with Preservative); strength: 50mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.3800; ministry $1.3800 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02536536 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102529
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02536536
Shortage record checked October 6, 2026

Other products in the same Health Canada class (R06A, R06AA): coverage varies; not interchangeable

  • Doxylamine + pyridoxine (Diclectin): general benefit
  • Meclizine (Bonamine): general benefit
Other drugs in the same formulary class (56:22 Antiemetics and Antinauseants) and how they are covered

Matched class: 56:22 Antiemetics and Antinauseants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DOXYLAMINE SUCCINATE AND PYRIDOXINE HCL, MECLIZINE HCL Some products covered without a code (check the product listing): NABILONE 56:22 Antiemetics and Antinauseants

DOXYLAMINE SUCCINATE AND PYRIDOXINE HCL

· 4 products · General benefit · strengths: 10mg & 10mg · SR Tab

MECLIZINE HCL

· 1 products · General benefit · strengths: 25mg · Tab

NABILONE

· 10 products · Off-Formulary Interchangeable, not an ODB benefit (4), General benefit (6) · strengths: 0.25mg, 0.5mg, 1mg · Cap

APREPITANT

· 1 products · Limited Use, codes 452, 453 · strengths: 125mg & 80mg · Cap

GRANISETRON HCL

· 4 products · Listed, not a benefit (1), Limited Use, codes 91, 92, 93, 326, 454 (3) · strengths: 1mg · Tab

NETUPITANT & PALONOSETRON HYDROCHLORIDE

· 1 products · Limited Use, codes 561, 562 · strengths: 300mg & 0.5mg · Cap

ONDANSETRON HYDROCHLORIDE

· 54 products · Listed, not a benefit (5), Limited Use, codes 215, 216, 217, 218, 454, 696 (49) · strengths: 4mg, 8mg, 4mg/5mL · O/L, Tab

ONDANSETRON HCL DIHYDRATE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2mg/mL · Inj Sol-2mL Pk, Inj Sol-4mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 56:22
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:40 Miscellaneous G.I. Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Dimenhydrinate Injection USP and Sandoz Dimenhydrinate (dimenhydrinate) are indicated for use in the prevention and relief of nausea, vomiting and/or vertigo. These symptoms may be associated with clinical situations such as motion sickness, radiation sickness, postoperative recovery, drug- induced nausea and vomiting, Ménière's disease and other labyrinthine disturbances. Parenteral therapy is available when rectal therapy is inappropriate. Geriatrics (> 65 years of age): See WARNINGS AND PRECAUTIONS —Special Populations, Geriatrics. Dimenhydrinate Injection USP and Sandoz Dimenhydrinate Page 3 of 24 Pediatrics: • < 2 years of age: The safety and efficacy of Dimenhydrinate Injection USP in children under the age of 2 have not been established. Dimenhydrinate Injection USP should not be used in this population. • < 12 years of age: The safety and efficacy of Sandoz Dimenhydrinate in children under the age of 12 have not been established. Sandoz Dimenhydrinate should not be used in this population. https://pdf.hres.ca/dpd_pm/00082621.PDF PM date: NOV 25, 2025 Source product: DIMENHYDRINATE INJECTION USP; DIN 00392537; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.